Germany’s CureVac vaccine against COVID-19 shows an effectiveness of 48% and this poor showing is driving a stock plunge.
Biotech firm CureVac said its coronavirus vaccine the 48% efficacy results from final analysis. It marks only a slight improvement on the company’s last trial.
CureVac announced the second- and third-phase trial results for its CVnCoV vaccine on Wednesday, says Reuters.
In March, it broadened its mRNA COVID vaccine trials to include new virus variants. There’s no idea whether the poor showing will hamper its attempts to file for EU approval in the second quarter.
Curevac also said in march it has signed a deal with Novartis for the Swiss pharmaceutical giant to help in its production of its vaccine.
“The Swiss giant will make up to 50 million doses of the mRNA vaccine by the end of 2021 and up to 200 million doses in 2022.” it said.
